- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Fund Finance
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- Innovation Protection
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Antitrust
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Corporate and Securities Litigation
- E-Discovery
- Global Construction and Infrastructure Disputes
- Innovation Protection
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy Transition
- Energy
- Financial Services
- Food and Beverage
- Higher Education
- Life Sciences and Healthcare
- Technology
- Artificial Intelligence (AI) and Machine Learning
- Buy American
- Crisis Management
- Doing Business in Latin America
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- Careers
- News & Insights
- About
- Languages
News 78 results
Recognition
April 17, 2026
Senior Advisor Kendrick Meek Honored by the Congressional Black Caucus Foundation
In the News · Source: Daily Mail
In the News · Source: The Free Press
In the News · Source: Law.com
February 3, 2026
K&S is highlighted in a profile examining how the firm’s lobbying income rose in 2025
In the News · Source: Managed Healthcare Executive
January 19, 2026
John Shakow and David Farber comment on the limitations of rebates and cost savings for health plans and patients under new Medicare drug programs
In the News · Source: The Free Press
Recognition
December 11, 2025
The Hill Names Allison Kassir a Top Lobbyist
In the News · Source: POLITICO and POLITICO Influence
Recognition
November 6, 2025
Best Lawyers Names King & Spalding Law Firm of the Year for FDA Law and Recognizes 41 Practices in its 2026 “Best Law Firms” Guide
In the News · Source: The Washington Post, Virginia Mercury, Blue Virginia, NBC Washington, FFX Now and WUSA9
October 17, 2025
K&S conducts an external investigation for Fairfax County Public Schools in response to two federal inquiries
In the News · Source: Politico
September 26, 2025
Tom Spulak comments on President Trump referencing FARA enforcement in a recent memorandum on tackling “domestic terrorism and organized political violence”
Recognition
September 12, 2025
King & Spalding Named Finalists for Three Honors at 2025 National Law Journal Awards